Abstract

Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment

Author(s): Riepl Mike

Issue: Mar/Apr 2023 - Volume 27, Number 2

Page(s): 98-107

Download in electronic PDF format for $75
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 1
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 2
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 3
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 4
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 5
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 6
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 7
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 8
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 9
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Page 10

Abstract

Described by some authors as a “black swan event . . . likened to the economic scene of World War Two,” the effects of coronavirus-disease–2019 (COVID-19) and attempted techniques for its prevention and treatment have presented medical, economic, social, and (often) politicized challenges on a global scale. Caused by the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 is, in many patients, associated with severe morbidity and mortality during the first few weeks after infection. At the time of this writing, estimates indicate that up to 70% of survivors may also experience “long COVID,” a condition that can persist for weeks, months, or years after virus-free status has been achieved, often produces severe symptoms across multiple organ systems, and can result in a wide variety of adverse outcomes. Scientific knowledge about COVID-19 and long COVID continues to evolve at a rate insufficient to address the protean manifestations and effects of continually emerging novel SARS-CoV-2 variants. When the recovery of afflicted patients is further challenged by intolerance to ingredients in (or available doses or dosage forms of) commercially manufactured medications that could provide therapeutic support, customized formulations may offer relief and enable healing. In this article, COVID-19 is addressed as an entity (i.e., the pandemic crisis it engendered is summarized to date, the most common signs and symptoms of that disease are described, and the phenomenon of cytokine storm in infected patients is examined), SARS-CoV-2 is discussed (i.e., common nomenclature systems used to describe and track that virus are presented and the processes of viral transmission, mechanisms of action, replication, and recombination are briefly reviewed), and the efficacy of a currently underappreciated agent (low-dose naltrexone) for the treatment of COVID-19 is considered. Two compounded formulations that can be used to treat the signs, symptoms, and/or sequelae of acute COVID-19 and/or long COVID are provided for easy reference.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2023
Pg. 98-107
Author(s): Riepl Mike
Jan/Feb 2023
Pg. 12-21
Author(s): Riepl Mike
Jul/Aug 2023
Pg. 284-293
Author(s): Riepl Mike, Kaiser Joe
May/Jun 2023
Pg. 192-200
Author(s): Riepl Mike, Kaiser Joe
Sep/Oct 2023
Pg. 368-380
Author(s): Riepl Mike, Kaiser Joe
Jul/Aug 2020
Pg. 287-295
Author(s): McElhiney Linda F
Jul/Aug 2020
Pg. 268
Author(s): Allen Loyd V Jr
Sep/Oct 2020
Pg. 358-364
Jul/Aug 2003
Pg. 288-291
Author(s): Glasnapp Andrew
Jul/Aug 2003
Pg. 266-270
Author(s): Kuntz Rachael
Mar/Apr 2021
Pg. 109-113
May/Jun 2003
Pg. 188-191
Author(s): Davidson Gigi S
Jul/Aug 2020
Pg. 316
Author(s): Allen Loyd V Jr
Jul/Aug 2021
Pg. 268
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 310
Author(s): Stockton Shelly J
May/Jun 2003
Pg. 170-174
Author(s): Meece Jerry
Jul/Aug 2021
Pg. 296-297
Author(s): Brunner Scott
Sep/Oct 2021
Pg. 386-387
Author(s): Brunner Scott
Mar/Apr 2022
Pg. 100-109
Author(s): Broughel James
Nov/Dec 2003
Pg. 426-435
View Sample
Author(s): Albright Lisa M